Salford Royal Hospital

Running trials

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)

  NCT07533006· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Spur Therapeutics· Source

• Recruiting

  Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

  NCT07123155· Phase 2· Shionogi· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

  NCT07091630· Phase 3· argenx· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

  NCT06920004· Phase 3· argenx· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Ambroxol to Slow Progression in Parkinson Disease

  NCT05778617· Phase 3· University College, London· Source

• Recruiting

  A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

  NCT06667453· Phase 2· PepGen Inc· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Understanding the Variation of Modern Endoscopic Ultrasound Use in Patients With Oesophageal Cancer (VALUE)

  NCT06440174· University Hospital Southampton NHS Foundation Trust· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

  NCT06545136· Phase 1/2· Spur Therapeutics· Source

• Active, not recruiting

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

  NCT06220201· Phase 1· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Active, not recruiting

  Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

  NCT06297603· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)

  NCT06185764· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

  NCT06143878· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  NCT06154252· Phase 2/3· Cabaletta Bio· Source

• Enrolling by invitation

  Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

  NCT06066580· Phase 2· Edgewise Therapeutics, Inc.· Source

• Active, not recruiting

  A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

  NCT06095115· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

  NCT06095102· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  NCT05797610· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  GEKO Venous Thromboembolism Prevention Study

  NCT05476913· Firstkind Ltd· Source

• Active, not recruiting

  Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

  NCT05696717· Phase 3· Theravance Biopharma· Source

• Recruiting

  A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  NCT05895786· Phase 3· Pfizer· Source

• Recruiting

  Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

  NCT04939935· Phase 3· The University of Queensland· Source

• Active, not recruiting

  A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

  NCT04020055· Phase 3· Amicus Therapeutics· Source

• Active, not recruiting

  Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

  NCT05481879· Phase 1/2· Dyne Therapeutics· Source

• Recruiting

  Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

  NCT04165486· Phase 1· Ionis Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque Psoriasis

  NCT03218488· Janssen-Cilag International NV· Source

• Recruiting

  The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)

  NCT03562169· Phase 3· University of Leeds· Source

• Active, not recruiting

  National Unified Renal Translation Research Enterprise - Chronic Kidney Disease

  NCT04084145· University of Nottingham· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Dermatomyositis and polymyositis (myositis)3 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Alopecia areata1 recruiting
• Childhood cancers1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Epilepsy1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gaucher disease1 recruiting
• Multiple myeloma1 recruiting
• Multiple system atrophy1 recruiting
• Myotonic dystrophy1 recruiting
• Parkinson disease1 recruiting
• Polycystic kidney disease1 recruiting
• Pompe disease1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

  NCT06204809· Phase 1· PepGen Inc· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  Efficacy and Safety Study of HRO350 in Patients with Mild-to-moderate Psoriasis (the 'HeROPA' Study).

  NCT06125808· Phase 2· Arctic Bioscience· Source

• Terminated

  Study of M5049 in DM and PM Participants (NEPTUNIA)

  NCT05650567· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

  NCT05291091· Phase 2· Edgewise Therapeutics, Inc.· Source

• Completed

  A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

  NCT05379634· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Study of ATH434 in Participants with Multiple System Atrophy

  NCT05109091· Phase 2· Alterity Therapeutics· Source

• Completed

  A Gene Therapy Study in Patients With Gaucher Disease Type 1

  NCT05324943· Phase 1· Spur Therapeutics· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Completed

  A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

  NCT06402630· Phase 2· Soterios Ltd· Source

• Completed

  Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC

  NCT05059327· Phase 2· Noema Pharma AG· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  Multiple Sclerosis-Simvastatin Trial 2

  NCT03387670· Phase 3· University College, London· Source

• Completed

  Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

  NCT02699645· Phase 3· The George Institute· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Alopecia areata7 works · 2 trials
• Dermatomyositis and polymyositis (myositis)6 works · 5 trials
• Gaucher disease4 works · 3 trials